HC Wainwright Raises Personalis (NASDAQ:PSNL) Price Target to $9.00

Personalis (NASDAQ:PSNL - Free Report) had its price objective raised by HC Wainwright from $8.00 to $9.00 in a research report report published on Wednesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also commented on PSNL. Needham & Company LLC reiterated a "buy" rating and issued a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Craig Hallum assumed coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective on the stock. Finally, Lake Street Capital increased their price objective on Personalis from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Personalis has an average rating of "Buy" and an average price target of $8.00.

Personalis Price Performance

Shares of PSNL traded up $0.20 during mid-day trading on Wednesday, reaching $5.24. The company had a trading volume of 333,229 shares, compared to its average volume of 1,000,900. The company has a market capitalization of $462.73 million, a P/E ratio of -3.11 and a beta of 1.83. Personalis has a twelve month low of $1.14 and a twelve month high of $7.20. The company's 50-day moving average is $3.67 and its 200-day moving average is $4.46.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The business had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. As a group, equities analysts expect that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Personalis during the 4th quarter worth $28,000. JPMorgan Chase & Co. raised its stake in Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after buying an additional 5,654 shares during the period. Olympiad Research LP acquired a new stake in shares of Personalis in the 4th quarter valued at about $59,000. Alpine Global Management LLC acquired a new stake in shares of Personalis in the 4th quarter valued at about $60,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Personalis in the 4th quarter valued at about $63,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.